Survival of hiv-infected adolescents on antiretroviral therapy in uganda: Findings from a nationally representative cohort in uganda

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Bakanda, Celestin ^a   Birungi, Josephine ^a   Mwesigwa, Robert ^a   Nachega, Jean B ^b   Chan, Keith ^c   Palmer, Alexis ^c   Ford, Nathan ^d   Mills, Edward J ^c,e  

^a THE AIDS SUPPORT ORGANIZATION   (Uganda)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; STAVUDINE; ZIDOVUDINE; ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; AGE; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PREDICTION; PROPORTIONAL HAZARDS MODEL; SCHOOL CHILD; SEX DIFFERENCE; SURVIVAL RATE; TREATMENT OUTCOME; UGANDA; CD4+ T LYMPHOCYTE; CYTOLOGY; DRUG COMBINATION; VIROLOGY;

ADOLESCENT; ADULT; AGE FACTORS; ANTI-RETROVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CHILD; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME; UGANDA;

EID: 79955772056     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019261     Document Type: Article

References (21)

1. Braitstein P, Brinkhof MWG, Dabis F, Schechter M, Boulle A, et al. (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367: 817-824.
2. Sauvageot D, Schaefer M, Olson D, Pujades-Rodriguez M, O'Brien DP, (2010) Antiretroviral Therapy Outcomes in Resource-Limited Settings for HIV-Infected Children <5 Years of Age. Pediatrics 125: E1039-E1047.
3. World Health Oganization (2007) Towards Universal Access: Scaling Up Priority HIV/AIDS Interventions in the Health Sector. Progress Report Geneva, Switzerland World Health Organization.
4. UNAIDS (2008) AIDS Epidemic Update Geneva, Switzerland World Health Organization.
5. Ferrand RA, Corbett EL, Wood R, Hargrove J, Ndhlovu CE, Gouws E, Williams BG, (2009) AIDS among older children and adolescents in Southern Africa: projecting the time course and magnitude of the epidemic. AIDS 23 (15): 2039-2046.
6. Wilson CM, Wright PF, Safrit JT, Rudy B, (2010) Epidemiology of HIV Infection and Risk in Adolescents and Youth. Journal of Acquired Immune Deficiency Syndromes 54: S5-S6.
7. World Health Organization (2007) Towards Universal Access: Scaling Up Priority HIV/AIDS Interventions in the Health Sector. Progress Report Geneva, Switzerland World Health Organization.
8. Flynn PM, Rudy BJ, Lindsey JC, Douglas SD, Lathey J, et al. (2007) Long-term observation of adolescents initiating HAART therapy: Three-year follow-up. AIDS Research and Human Retroviruses 23: 1208-1214.
9. Murphy DA, Wilson CM, Durako SJ, Muenz LR, Belzer M, (2001) Adolescent Medicine HIV/AIDS Research Network. Antiretroviral medication adherence among REACH HIV-infected adolescent cohort in the USA. AIDS Care 13: 27-40.
10. Rongkavilit C, Naar-King S, Chuenyam T, Wang B, Wright K, et al. (2007) Health risk behaviors among HIV-infected youth in Bangkok, Thailand. J Adolesc Health 40: 1-8.
11. Charles M, Noel F, Leger P, Severe P, Riviere C, et al. (2008) Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretrovirals. Bulletin of the World Health Organization 86: 909-88.
12. Murphy DA, Sarr M, Durako SJ, Moscicki AB, Wilson CM, et al. (2003) Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med 157: 249-255.
13. Nachega JB, Hislop M, Nguyen H, Dowdy DW, Chaisson RE, et al. (2009) Antiretroviral Therapy Adherence, Virologic and Immunologic Outcomes in Adolescents Compared With Adults in Southern Africa. Journal of Acquired Immune Deficiency Syndromes 51: 65-71.
14. Uganda Ministry of Health (2003) National antiretroviral treatment and care guidelines for adults and children. http://www.aidsuganda.org/pdf/ARV_Clinical_Guidelines_Final_draft.pdf Accessed November 29, 2010.
15. Kiboneka A, Nyatia R, Nabiryo C, Montaner J, Cooper C, et al. (2009) Combination antiretroviral therapy in population affected by conflict: outcomes from large cohort in northern Uganda. BMJ 338: b201.
16. Kiboneka A, Wangisi J, Nabiryo C, Tembe J, Kusemererwa S, et al. (2008) Clinical and immunological outcomes of a national paediatric cohort receiving combination antiretroviral therapy in Uganda. AIDS 22: 2493-2499.
17. Allison PD, (1995) Survival analysis using SAS: a practical guide Cary, North Carolina SAS Institute Inc.
18. Brinkhof MW, Pujades-Rodriguez M, Egger M, (2009) Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One 4: e5790.
19. Perinatial Health Research Unit: Kganya Motsha Adolscent Centre Soweto, South Africa (2010) http://phru.co.za/component/content/article/35/67-prevention.html Accessed December 1, 2010.
20. May M, Boulle A, Phiri S, Messou E, Myer L, et al. (2010) Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet 376: 449-457.
21. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, et al. (2006) Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 367: 1335-1342.